Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

被引：0

作者：

Huang, M. J. ^{[1
,2
]}

Yu, M. ^{[1
,2
]}

Gong, Y. L. ^{[2
,3
]}

Li, Y. Y. ^{[2
]}

Liu, Y. M. ^{[2
]}

Peng, F. ^{[2
]}

Yu, Y. ^{[2
]}

Xiu, W. G. ^{[2
]}

Wang, Y. S. ^{[2
,4
]}

Zou, B. W. ^{[2
]}

Fan, H. ^{[5
]}

Zhong, L. Q. ^{[6
]}

Liu, T. Q. ^{[7
]}

Wang, X. F. ^{[8
]}

Xu, Y. ^{[2
]}

Zhou, L. ^{[2
]}

Lu, Y. ^{[1
,3
,9
]}

机构：

[1] Sichuan Univ, West China Hosp, Div Thorac Tumor Multimodal Treatment, Ctr Canc, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Ctr Canc, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Clin Res, Chengdu, Peoples R China

[5] Peoples Hosp Leshan, Leshan, Peoples R China

[6] Yibin Second Peoples Hosp, Yibin, Peoples R China

[7] Hosp Shimian Cty, Yaan, Peoples R China

[8] Sichuan Sci City Hosp, Chengdu, Peoples R China

[9] Sichuan Univ, West China Hosp, Lab Clin Cell Therapy, Chengdu, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

aumolertinib; icotinib; central nervous system metastases;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA13.05

引用

下载

页码：S146 / S146

页数：1

共 50 条

[21] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, Sophie
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
[22] Lifetime incidence of brain metastases (BM) in EGFR-mutant (M plus ) lung cancer treated with first-line EGFR TKIs
Ng, D. Z.
Tan, W. L.
Ong, W. S.
Gan, E. M.
Jain, A.
Tan, E. -H.
Tan, D.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S117
[23] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
Fang, S.
Xu, T.
Zhao, X.
Liu, N.
Wang, X.
Cheng, W.
Fang, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
[24] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
Xu, Q.
Liu, H.
Hang, T.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
[25] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul, S.
Mun, T. L.
Wang, C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
[26] Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
Luo, F.
Liu, Y. Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S672
[27] Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG 51403
Goldberg, Sarah
Moon, James
Lilenbaum, Rogerio
Politi, Katerina
Melnick, Mary Ann
Stinchcombe, Thomas
Horn, Leora
Chen, Everett
Miao, Jieling
Redman, Mary
Kelly, Karen
Gandara, David R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1220 - S1221
[28] Apatinib Plus Icotinib as First-Line Therapy For EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study
Shang, Y.
Li, X.
Huo, R.
Ji, M.
Song, Z.
Liu, B.
Jia, Y.
Li, Y.
Jiao, J.
Shi, J.
Zhang, Y.
Chen, X.
Yao, M.
Zhang, X.
Zang, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S984 - S984
[29] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
Cortot, Alexis B.
Moro-Sibilot, Denis
Cadranel, Jacques
CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
[30] Aumolertinib in Treatment-Naive EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Wang, H.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S397 - S398

← 1 2 3 4 5 →